Alimentary Pharmacology & Therapeutics

Review article: a conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus
pp. 1087-1100(14)
Authors: Souza, R. F.; Morales, C. P.; Spechler, S. J.

Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment
pp. 1101-1108(8)
Authors: Aithal, G. P.; Mansfield, J. C.

Review article: transfusion in gastrointestinal haemorrhage—if, when and how much?
pp. 1109-1113(5)
Author: Duggan, J. M.

Review article: lymphatic vessel pumping and inflammation—the role of spontaneous constrictions and underlying electrical pacemaker potentials
pp. 1115-1129(15)
Author: Von Der Weid, P.-Y.

Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy
pp. 1131-1137(7)
Authors: Fraser, J. S.; Muller, A. F.; Smith, D. J.; Newman, D. J.; Lamb, E. J.

A study of fructo oligosaccharides in the prevention of travellers' diarrhoea
pp. 1139-1145(7)
Authors: Cummings, J. H.; Christie, S.; Cole, T. J.

Anal sphincter biofeedback and pelvic floor exercises for faecal incontinence in adults—a systematic review
pp. 1147-1154(8)
Authors: Norton, C.; Kamm, M. A.

Ambulatory gastric pH monitoring: proper probe placement and normal values
pp. 1155-1162(8)
Authors: Fackler, W. K.; Vaezi, M. F.; Richter, J. E.

Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis
pp. 1163-1175(13)
Authors: Sanduleanu, S.; Jonkers, D.; De Bruïne, A.; Hameeteman, W.; Stockbrügger, R. W.

There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia
pp. 1177-1185(9)
Authors: Des Varannes, S. Bruley; Fléjou, J. F.; Colin, R.; Zaïm, M.; Meunier, A.; Bidaut-Mazel, C.

Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen
pp. 1187-1191(5)
Authors: Adachi, K.; Ishihara, S.; Hashimoto, T.; Hirakawa, K.; Ishimura, N.; Niigaki, M.; Kaji, T.; Kawamura, A.; Sato, H.; Fujishiro, H.; Hattori, S.; Watanabe, M.; Kinoshita, Y.

A triple therapy regimen after failed Helicobacter pylori treatments
pp. 1193-1197(5)
Authors: Zullo, A.; Hassan, C.; Campo, S. M. A.; Lorenzetti, R.; Febbraro, I.; De Matthaeis, M.; Porto, D.; Morini, S.

Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori
pp. 1199-1204(6)
Authors: Bardhan, K. D.; Morton, D.; Perry, M. J.; Sanders, D. S.; Morris, P.; Rowland, A.; Thompson, M.; Mitchell, T. R.; Roberts, P. M.

Helicobacter pylori testing in the primary care setting: which diagnostic test should be used?
pp. 1205-1210(6)
Authors: Weijnen, C. F.; De Wit, N. J.; Numans, M. E.; Kuipers, E. J.; Hoes, A. W.; Verheij, T. J. M.

Glucocorticoids and IL-10, but not 6-MP, 5-ASA or sulfasalazine block endothelial expression of MAdCAM-1: implications for inflammatory bowel disease therapy
pp. 1211-1218(8)
Authors: Oshima, T.; Pavlick, K.; Grisham, M. B.; Jordan, P.; Manas, K.; Joh, T.; Itoh, M.; Alexander, J. S.

Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice
pp. 1219-1225(7)
Authors: O'Mahony, L.; Feeney, M.; O'Halloran, S.; Murphy, L.; Kiely, B.; Fitzgibbon, J.; Lee, G.; O'Sullivan, G.; Shanahan, F.; Collins, J. K.

Interleukin-8 increases acetylcholine response of rat intestinal segments
pp. 1227-1232(6)
Authors: Plattner, V.; Leray, V.; Leclair, M.-D.; Aubé, A.-C.; Cherbut, C.; Galmiche, J. P.

Duodenogastric reflux following cholecystectomy in the dog: role of antroduodenal motor function
pp. 1233-1238(6)
Authors: Nogi, K.; Haruma, K.; Taniguchi, H.; Yomota, E.; Okajima, M.; Hananoki, M.; Hata, J.; Kusunoki, H.; Onoda, Y.